Impilo joins the ESG Data Convergence Initiative reaffirms commitment to ESG disclosure and standardization

Impilo AB, today announced that it has joined the ESG Data Convergence Initiative, a global effort to improve ESG (Environmental, Social, and Governance) data standardization and disclosure.

The ESG Data Convergence Initiative (EDCI) is an open partnership of private equity industry stakeholders committed to streamlining the industry’s approach to collecting and reporting on ESG. It brings together more than 275 General & Limited Partners with some $26tn asset under management, and more than 2000 portfolio companies. By joining this initiative, Impilo underscores its commitment to transparency, accountability, and sustainability, and its belief that standardized ESG data is crucial for informed decision-making.

Impilo’s Managing Partner, Fredrik Strömholm comments:

“Joining the ESG Data Convergence Initiative is an important step on our sustainability journey. We believe that managing ESG factors is essential to long-term business success and that it will contribute to a more sustainable healthcare system. The disclosure of our performance is critical, and we are committed to providing investors with accurate, reliable, and comparable ESG data. By working with other leading companies and stakeholders in this initiative, we can help shape the future of ESG data reporting and improve the quality and accessibility of ESG information.”

As part of its commitment to ESG disclosure and standardization, Impilo has already taken a number of steps to enhance its ESG reporting, including requiring portfolio companies to disclose performance against the EDCI indicators as well as a number of other ESG indicators, reporting regularly to investors on portfolio companies’ performance on the Impilo Sustainability Blueprint, and by publishing an annual sustainability report. In addition, Impilo works with its portfolio companies to demonstrate how they contribute to creating health impact. Read more about how we work with promoting health impact and advancing sustainability in our annual sustainability report for 2022.


Contact details
Fredrik Strömholm, Managing Partner, Impilo, +46-76 115 10 65,

Martin Fagerlund, COO & Partner, Impilo, +46-70 943 23 30,


About Impilo
Impilo is a Nordic investment company focused on investments in sustainable healthcare companies active in the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo strives to increase value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of healthcare investments and manages c. EUR 1 billion of capital from leading Nordic and international investors.


KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma

Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.

Read article

Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform

Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.

Read article

Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)

Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.

Read article